JNJ-37822681

Generic Name: JNJ-37822681

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₇F_₅N_₄

CAS Number: 935776-74-2

Unique Ingredient Identifier: GJB2URS7NJ

Background: JNJ-37822681 has been used in trials studying the treatment of Schizophrenia.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: JNJ-37822681
Other: Placebo

First Posted Date: 2013-03-18

Last Posted Date: 2014-03-18

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 33

Registration Number: NCT01812642

An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: JNJ-37822681
Drug: Olanzapine
Drug: Placebo

First Posted Date: 2008-08-05

Last Posted Date: 2014-03-26

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 498

Registration Number: NCT00728195

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy